Akeso Details Long-Term MAb Contract Manufacturing and Demand Assumptions

Akeso, Inc. ( (HK:9926) ) just unveiled an update.

Akeso, Inc. has provided additional details on its long-term contract manufacturing arrangement involving CTTQ-Akeso, Akeso Biopharma, Chai Tai Tianqing and Nanjing Tianqing, clarifying that the supplemental agreement for MAb product manufacturing runs until August 29, 2039, with the option for the parties to negotiate a new agreement upon expiry, subject to compliance with Hong Kong listing requirements. The company elaborated that procurement pricing for MAb products will be based on Nanjing Tianqing’s actual manufacturing costs plus a reasonable profit margin benchmarked against listed contract manufacturers, and that proposed annual procurement caps factor in expected demand growth driven by the inclusion of penpulimab in China’s National Reimbursement Drug List from January 2026, anticipated new indications, potential new markets, and a single-digit buffer for unforeseen increases, while also disclosing more detail on the shareholder structure of Chia Tai Tianqing.

The most recent analyst rating on (HK:9926) stock is a Hold with a HK$116.00 price target. To see the full list of analyst forecasts on Akeso, Inc. stock, see the HK:9926 Stock Forecast page.

More about Akeso, Inc.

Akeso, Inc. is a biopharmaceutical company focused on the development and commercialization of monoclonal antibody (MAb) therapies, including its PD-1 monoclonal antibody product penpulimab, with a key market focus on the Chinese healthcare sector. The company collaborates with contract manufacturing partners such as Nanjing Tianqing and operates through joint ventures like CTTQ-Akeso to scale production and distribution of its MAb portfolio in China.

Average Trading Volume: 6,297,795

Technical Sentiment Signal: Buy

Current Market Cap: HK$107.3B

Learn more about 9926 stock on TipRanks’ Stock Analysis page.